Earnings call transcript: Conagra beats Q1 2026 EPS forecast as shares fall

Conagra reported fiscal Q1 2027 adjusted EPS of $0.41, beating the $0.28 consensus by 46.4%, while revenue of $2.6 billion narrowly exceeded forecasts; shares nevertheless fell 3.96% to $13.57. Organic sales declined 1.1% and volume fell 2.1%, underscoring weak consumer demand, while adjusted operating margin declined 33bps year over year to 11.5%. Management reaffirmed FY2027 guidance for organic sales to decline 1%-3%, EPS of $1.40-$1.50, and operating margin of 10.0%-10.5%, with inflation expected at 5%-6% amid logistics, fuel, packaging and edible-oil cost pressures.

Analysis

CAG’s earnings quality is weaker than the headline beat: the upside was aided by non-core/volatile items and favorable expense timing while underlying retail volumes remain under pressure. The critical near-term setup is a margin trough in Q2 as pricing, fuel/logistics inflation, stepped-up advertising and the reversal of Q1 timing benefits converge. That creates downside risk to sell-side estimates if investors are still underwriting a smooth progression toward the full-year midpoint.

The more material 6-18 month question is whether SKU rationalization can convert a fragmented portfolio into lower manufacturing and procurement costs without forfeiting shelf space. Retailers may reallocate discontinued facings to private label or scaled branded peers such as General Mills (GIS), Campbell’s (CPB), and Kraft Heinz (KHC), making volume recovery harder even if CAG’s internal cost structure improves. The planned portfolio review is a potential rerating catalyst only if divestiture proceeds are demonstrably directed to debt reduction; at roughly 4x leverage, the equity remains unusually exposed to any sustained margin miss or rates-driven increase in refinancing costs.

Contrarianly, the selloff may be approaching a valuation floor if free-cash-flow conversion holds and management can show that elasticity moderates after the pricing reset. But the high indicated cash yield should not be treated as a clean value signal until Q2 confirms that working-capital release, joint-venture earnings and one-time cost items are not masking weaker recurring cash generation. January’s Investor Day is the first credible venue for targets on asset sales, SKU reduction, supply-chain savings and leverage; absent quantified milestones, the restructuring narrative deserves little multiple expansion.

Key Decisions for Investors

• Remain underweight CAG through Q2 results; avoid buying the post-earnings dip before the expected high-single-digit operating-margin quarter. Reassess only if Q2 retail consumption/share data stabilize and management maintains the FY EPS range without further reliance on joint-venture income.
• Use a tactical pair trade: long GIS / short CAG over the next 1-3 months. GIS offers a more defensive earnings profile while CAG faces a concentrated execution and leverage test; target 8-12% relative upside, with a stop if CAG demonstrates sequential volume improvement and reiterates margin recovery after Q2.
• For value accounts, set a CAG entry alert near the prior-cycle low rather than initiating now; require evidence that net leverage is moving toward 3x and that free cash flow is covering dividends, capex and debt reduction. Upside case is multiple normalization into the January Investor Day; downside is a guidance cut following Q2.
• Monitor freight/fuel and edible-oil inputs weekly, plus Nielsen/IRI category shares in frozen meals, popcorn and meat snacks. A renewed input-cost spike or measurable shelf-share loss after SKU exits falsifies the margin-recovery thesis and warrants maintaining the short leg.